CAMBRIDGE, England--(BUSINESS WIRE)--Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D genome for use in novel target identification and unique patient stratification, ...

Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships CAMBRIDGE, England--(BUSINESS WIRE) ...

Fox Chase Cancer Center and Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced that ...

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug ...

The biggest challenge in drug development is that the process is not an even balance of hit or miss – it is overwhelmingly miss, with around 90% of drugs never making it beyond clinical trials. As a ...

Fox Chase will use Arima's 3D genomics technology as part of its diagnostic workflow for lymphoma and sarcoma.

In particular, genome-wide association studies (GWAS) have pinpointed hundreds of genes associated with disease risk, enabling the development of drugs targeting a broad range of highly prevalent ...